vs
DigitalOcean Holdings, Inc.（DOCN）与Prestige Consumer Healthcare Inc.（PBH）财务数据对比。点击上方公司名可切换其他公司
Prestige Consumer Healthcare Inc.的季度营收约是DigitalOcean Holdings, Inc.的1.2倍（$283.4M vs $242.4M），Prestige Consumer Healthcare Inc.净利率更高（16.5% vs 10.6%，领先5.9%），DigitalOcean Holdings, Inc.同比增速更快（18.3% vs -2.4%），Prestige Consumer Healthcare Inc.自由现金流更多（$75.3M vs $31.1M），过去两年DigitalOcean Holdings, Inc.的营收复合增速更高（14.5% vs 1.2%）
DigitalOcean Holdings, Inc.是美国跨国科技企业及云服务提供商，总部位于美国科罗拉多州布鲁姆菲尔德，在全球布局15个数据中心，面向开发者、初创企业及中小微企业提供稳定易用的云基础设施即服务平台，助力各类技术团队高效开展业务。
Prestige Consumer Healthcare Inc.是一家美国企业，主营非处方健康护理产品及家用清洁产品的营销与分销业务。该公司于1996年由Medtech Products、Prestige Brands International及Spic and Span三家公司合并成立，总部位于纽约州塔里敦，在弗吉尼亚州林奇堡设有生产工厂。
DOCN vs PBH — 直观对比
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $242.4M | $283.4M |
| 净利润 | $25.7M | $46.7M |
| 毛利率 | 58.7% | 55.5% |
| 营业利润率 | 16.0% | 29.1% |
| 净利率 | 10.6% | 16.5% |
| 营收同比 | 18.3% | -2.4% |
| 净利润同比 | 40.5% | -23.5% |
| 每股收益（稀释后） | $0.23 | $0.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $242.4M | $283.4M | ||
| Q3 25 | $229.6M | $274.1M | ||
| Q2 25 | $218.7M | $249.5M | ||
| Q1 25 | $210.7M | $296.5M | ||
| Q4 24 | $204.9M | $290.3M | ||
| Q3 24 | $198.5M | $283.8M | ||
| Q2 24 | $192.5M | $267.1M | ||
| Q1 24 | $184.7M | $277.0M |
| Q4 25 | $25.7M | $46.7M | ||
| Q3 25 | $158.4M | $42.2M | ||
| Q2 25 | $37.0M | $47.5M | ||
| Q1 25 | $38.2M | $50.1M | ||
| Q4 24 | $18.3M | $61.0M | ||
| Q3 24 | $32.9M | $54.4M | ||
| Q2 24 | $19.1M | $49.1M | ||
| Q1 24 | $14.1M | $49.5M |
| Q4 25 | 58.7% | 55.5% | ||
| Q3 25 | 59.6% | 55.3% | ||
| Q2 25 | 59.9% | 56.2% | ||
| Q1 25 | 61.4% | 57.3% | ||
| Q4 24 | 57.1% | 55.5% | ||
| Q3 24 | 60.2% | 55.5% | ||
| Q2 24 | 61.0% | 54.7% | ||
| Q1 24 | 60.7% | 54.8% |
| Q4 25 | 16.0% | 29.1% | ||
| Q3 25 | 19.6% | 29.1% | ||
| Q2 25 | 16.3% | 28.8% | ||
| Q1 25 | 17.9% | 29.8% | ||
| Q4 24 | 15.9% | 31.7% | ||
| Q3 24 | 12.4% | 29.7% | ||
| Q2 24 | 11.6% | 27.0% | ||
| Q1 24 | 6.2% | 29.7% |
| Q4 25 | 10.6% | 16.5% | ||
| Q3 25 | 69.0% | 15.4% | ||
| Q2 25 | 16.9% | 19.0% | ||
| Q1 25 | 18.1% | 16.9% | ||
| Q4 24 | 8.9% | 21.0% | ||
| Q3 24 | 16.6% | 19.2% | ||
| Q2 24 | 9.9% | 18.4% | ||
| Q1 24 | 7.7% | 17.9% |
| Q4 25 | $0.23 | $0.97 | ||
| Q3 25 | $1.51 | $0.86 | ||
| Q2 25 | $0.39 | $0.95 | ||
| Q1 25 | $0.39 | $1.00 | ||
| Q4 24 | $0.21 | $1.22 | ||
| Q3 24 | $0.33 | $1.09 | ||
| Q2 24 | $0.20 | $0.98 | ||
| Q1 24 | $0.15 | $0.98 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $254.5M | $62.4M |
| 总债务越低越好 | $1.3B | $1.0B |
| 股东权益账面价值 | $-28.7M | $1.8B |
| 总资产 | $1.8B | $3.5B |
| 负债/权益比越低杠杆越低 | — | 0.56× |
8季度趋势，按日历期对齐
| Q4 25 | $254.5M | $62.4M | ||
| Q3 25 | $236.6M | $119.1M | ||
| Q2 25 | $387.7M | $139.5M | ||
| Q1 25 | $360.4M | $97.9M | ||
| Q4 24 | $428.4M | $50.9M | ||
| Q3 24 | $439.9M | $51.5M | ||
| Q2 24 | $443.1M | $34.3M | ||
| Q1 24 | $419.1M | $46.5M |
| Q4 25 | $1.3B | $1.0B | ||
| Q3 25 | $1.3B | $993.1M | ||
| Q2 25 | — | $992.7M | ||
| Q1 25 | — | $992.4M | ||
| Q4 24 | $1.5B | $992.0M | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $1.1B |
| Q4 25 | $-28.7M | $1.8B | ||
| Q3 25 | $-69.6M | $1.8B | ||
| Q2 25 | $-175.2M | $1.9B | ||
| Q1 25 | $-210.7M | $1.8B | ||
| Q4 24 | $-203.0M | $1.8B | ||
| Q3 24 | $-211.7M | $1.7B | ||
| Q2 24 | $-253.8M | $1.7B | ||
| Q1 24 | $-286.1M | $1.7B |
| Q4 25 | $1.8B | $3.5B | ||
| Q3 25 | $1.7B | $3.4B | ||
| Q2 25 | $1.7B | $3.4B | ||
| Q1 25 | $1.6B | $3.4B | ||
| Q4 24 | $1.6B | $3.3B | ||
| Q3 24 | $1.5B | $3.3B | ||
| Q2 24 | $1.5B | $3.3B | ||
| Q1 24 | $1.5B | $3.3B |
| Q4 25 | — | 0.56× | ||
| Q3 25 | — | 0.54× | ||
| Q2 25 | — | 0.54× | ||
| Q1 25 | — | 0.54× | ||
| Q4 24 | — | 0.55× | ||
| Q3 24 | — | 0.61× | ||
| Q2 24 | — | 0.65× | ||
| Q1 24 | — | 0.68× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $57.3M | $78.3M |
| 自由现金流经营现金流 - 资本支出 | $31.1M | $75.3M |
| 自由现金流率自由现金流/营收 | 12.8% | 26.6% |
| 资本支出强度资本支出/营收 | 10.8% | 1.1% |
| 现金转化率经营现金流/净利润 | 2.23× | 1.68× |
| 过去12个月自由现金流最近4个季度 | $180.5M | $267.2M |
8季度趋势，按日历期对齐
| Q4 25 | $57.3M | $78.3M | ||
| Q3 25 | $95.8M | $57.5M | ||
| Q2 25 | $92.4M | $79.0M | ||
| Q1 25 | $64.1M | $61.8M | ||
| Q4 24 | $71.3M | $65.1M | ||
| Q3 24 | $73.4M | $69.8M | ||
| Q2 24 | $71.3M | $54.8M | ||
| Q1 24 | $66.7M | $66.9M |
| Q4 25 | $31.1M | $75.3M | ||
| Q3 25 | $88.0M | $55.4M | ||
| Q2 25 | $59.3M | $78.2M | ||
| Q1 25 | $2.1M | $58.4M | ||
| Q4 24 | $26.1M | $63.5M | ||
| Q3 24 | $16.0M | $67.8M | ||
| Q2 24 | $39.5M | $53.6M | ||
| Q1 24 | $23.0M | $63.8M |
| Q4 25 | 12.8% | 26.6% | ||
| Q3 25 | 38.3% | 20.2% | ||
| Q2 25 | 27.1% | 31.3% | ||
| Q1 25 | 1.0% | 19.7% | ||
| Q4 24 | 12.7% | 21.9% | ||
| Q3 24 | 8.1% | 23.9% | ||
| Q2 24 | 20.5% | 20.1% | ||
| Q1 24 | 12.5% | 23.0% |
| Q4 25 | 10.8% | 1.1% | ||
| Q3 25 | 3.4% | 0.8% | ||
| Q2 25 | 15.2% | 0.3% | ||
| Q1 25 | 29.4% | 1.2% | ||
| Q4 24 | 22.1% | 0.5% | ||
| Q3 24 | 28.9% | 0.7% | ||
| Q2 24 | 16.6% | 0.4% | ||
| Q1 24 | 23.6% | 1.1% |
| Q4 25 | 2.23× | 1.68× | ||
| Q3 25 | 0.60× | 1.36× | ||
| Q2 25 | 2.50× | 1.66× | ||
| Q1 25 | 1.68× | 1.23× | ||
| Q4 24 | 3.91× | 1.07× | ||
| Q3 24 | 2.23× | 1.28× | ||
| Q2 24 | 3.73× | 1.12× | ||
| Q1 24 | 4.72× | 1.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOCN
| Scalers | $84.3M | 35% |
| Scalers Plus | $69.9M | 29% |
| Builders | $64.1M | 26% |
| Learners Testers And Other | $24.1M | 10% |
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
